No I’m not wrong. I said it wasn’t a primary outcome. The primary outcome for the study was further understanding pharmacodynamics and MOA. From the beginning of preclinical safety testing, Kevetrin was not meant to be a stand-alone drug, though there was hope it might arrest or reduce tumors on its own without further intervention, especially for those patients having already exhausted all options. Kevetrin efficacy has always been, and continues to be, p53 modulation. Kevetrin clearly is efficacious. Your statement that it has no efficacy demonstrates a clear misunderstanding of what Kevetrin is supposed to do, actually does and it’s value to a BP.
Market Data 
Markets 
AI
